Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Doxorubicin Stories

2011-10-11 07:46:00

CAMBRIDGE, Mass., Oct. 11, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a randomized Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, combined with paclitaxel (Taxol®) in the neoadjuvant setting of HER2-negative breast cancer patients. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) The Phase 2 study is designed to evaluate whether the combination of...

2011-10-07 05:48:08

(Ivanhoe Newswire) -- The future looks bright for patients with HER2-positive breast cancer. A paper published in the October 6, 2011 issue of the New England Journal of Medicine (NEJM), shows that new treatment regimens, providing a lower risk of cardio toxicity, are an acceptable and effective option for patients. The new study, by the Breast Cancer International Research Group, answers a critical question raised by four previously published trials; are adjuvant anthracyclines necessary...

2011-10-06 09:54:37

Treating women with early stage breast cancer with a combination of chemotherapy and the molecularly targeted drug Herceptin significantly increases survival in patients with a specific genetic mutation that results in very aggressive disease, a researcher with UCLA's Jonsson Comprehensive Cancer Center reported Wednesday. The study also found that a regimen without the drug Adriamycin, an anthracycline commonly used as a mainstay to treat breast cancer but one that, especially when paired...

2011-10-03 11:49:59

A combination of an oral drug, called sorafenib, and a method for injecting microbeads of chemotherapy directly into tumors has been proven safe for liver cancer patients and may improve outcomes for those who have these fast-growing, deadly tumors whose numbers are on the rise in the U.S. Reporting in the Sept. 12 online version of the Journal of Clinical Oncology, Johns Hopkins investigators tested the combination in 35 patients with advanced, inoperable liver cancer. Both sorafenib and...

2011-09-28 11:37:39

Breast cancer cells that mutate to resist drug treatment survive by establishing tiny pumps on their surface that reject the drugs as they penetrate the cell membrane — making the cancer insensitive to chemotherapy drugs even after repeated use. Researchers have found a new way to break that resistance and shut off the pumps by genetically altering those breast cancer cells to forcibly activate a heat-shock protein called Hsp27. This protein regulates several others, including the...

2011-09-28 00:30:00

SEATTLE, Sept. 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that a second independent radiology assessment of response and progression endpoint data from CTI's PIX301 clinical trial of pixantrone confirmed the statistical robustness of the PIX301 efficacy data that was previously submitted by CTI to the U.S. Food and Drug Administration ("FDA") in CTI's new drug application ("NDA") for pixantrone. This second independent assessment was...

2011-09-26 06:00:00

QUÓ°BEC CITY, Sept. 23, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), today announced positive interim data for the Phase 1 portion of its ongoing Phase 1/2 study in castration and taxane-resistant prostate cancer with its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108. The data were presented by Jacek Pinski, M.D, Associate Professor of Medicine at the Norris Comprehensive Cancer...

2011-09-14 05:30:00

Encouraging data observed in overall survival and tolerability Company has requested Parallel Scientific Advice from FDA and EMA for pivotal trial QUÓ°BEC CITY, Sept. 14, 2011 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. The trial,...

2011-08-23 00:30:00

SEATTLE, Aug. 23, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) today announced that it has submitted its response to the Day 120 List of Outstanding Issues to the European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use ("CHMP") in regards to CTI's Marketing Authorization Application for pixantrone (the "MAA") to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL"). With this submission, CTI expects to receive...

2011-08-09 00:00:28

Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals Cambridge, MA (PRWEB) August 08, 2011 Merrimack Pharmaceuticals, Inc. announced today that the first patient has been dosed in a Phase I clinical trial of MM-302, a nanotherapeutic encapsulation of doxorubicin with attached antibodies that target the ErbB2 (HER2) receptor. The Phase 1 study in patients with advanced ErbB2 positive breast cancer is designed to evaluate the...